EE+ POEM Archive
Mepolizumab provides modest benefit for patients with severe eosinophilic asthma
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Mepolizumab Provides Modest Benefit for Patients With Severe Eosinophilic Asthma." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/428209/all/Mepolizumab_provides_modest_benefit_for_patients_with_severe_eosinophilic_asthma.
Mepolizumab provides modest benefit for patients with severe eosinophilic asthma. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428209/all/Mepolizumab_provides_modest_benefit_for_patients_with_severe_eosinophilic_asthma. Accessed April 24, 2024.
Mepolizumab provides modest benefit for patients with severe eosinophilic asthma. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428209/all/Mepolizumab_provides_modest_benefit_for_patients_with_severe_eosinophilic_asthma
Mepolizumab Provides Modest Benefit for Patients With Severe Eosinophilic Asthma [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 April 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428209/all/Mepolizumab_provides_modest_benefit_for_patients_with_severe_eosinophilic_asthma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Mepolizumab provides modest benefit for patients with severe eosinophilic asthma
ID - 428209
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428209/all/Mepolizumab_provides_modest_benefit_for_patients_with_severe_eosinophilic_asthma
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
